跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
NMPA
/
Recombinant Human Insulin Injection
Approved
生物制品
Recombinant Human Insulin Injection
Novo Nordisk A/S
🇨🇳 National Medical Products Administration
Approval Date
Aug 22, 2022
Approval ID
8JajfXhecSg
Company
Novo Nordisk A/S
Type
生物制品
Approval Details
Approval Id
8JajfXhecSg
Approval Number
国药准字SJ20201025
Generic Name
人胰岛素注射液
Generic Name En
Recombinant Human Insulin Injection
Trade Name
诺和灵R
Drug Type
生物制品
Dosage Form
注射剂
Strength
300IU/3ml/支(笔芯)
Reg Date
2022-08-22
Expired Date
2027-08-21
Company Name
Novo Nordisk A/S
Production Company Name
Novo Nordisk A/S
Company Detail Path
/organization/novo-nordisk-a-s
Production Company Detail Path
/organization/novo-nordisk-a-s
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Aug 22, 2022
Approval ID
8JajfXhecSg
Type
生物制品
Back to NMPA Approvals
诺和灵R - NMPA Drug Approval Details